★★★★★ 4
Almost good
Item Package Quantity: 1
They worked kinda good
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 14, 2026
retatrutide triple agonist glp-1 gip glucagon receptor Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research
Marsoni
M251S
Get it in 3 business days with 1 day shipping.
Friday, May 29
retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP 1 receptor. 22 24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter Researchers reveal benefits, risks linked to popular weight loss drugs The Brighter Side of News GLP 1 programs the neurovascular landscape: Cell Metabolism Emerging Trends in the Development of GLP 1 Receptor Agonists Biopharma PEG
Quick Dispatch:
Your retatrutide triple agonist glp-1 gip glucagon receptor Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research orders ship within 1-2 business days.
Delivery Options:
- Standard: 3-7 business days
- Fast: 2-3 business days
- Express: 1-2 business days
Order Tracking:
You'll receive a tracking link by email once your retatrutide triple agonist glp-1 gip glucagon receptor Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research ships.
Need Help?
Questions about retatrutide triple agonist glp-1 gip glucagon receptor Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for retatrutide triple agonist glp-1 gip glucagon receptor Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research in your area.
Get Shipping Estimates
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair
26.29
Retatrutide Beat Semaglutide by 7.9% in Phase 2 — Here's the Trial Data
24.47
🚨 HOT OFF THE PRESS: Retatrutide Phase 3 data has arrived — and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average
24.87
Strategic Design of Triple GLP-1R/GCGR/GIPR Agonists with Varied Receptor Potency: Achieving Comparable Glycemic and Weight Reduction Effects
28.51
Demonstrated metabolic effects of GIP, GLP-1 and GCG agonism as mono,
22.21
Retatrutide 10mg Pen (1-Month Supply) Advancing the future of metabolic health Retatrutide is a next-generation therapy designed to target three key metabolic pathways—offering a more comprehensive approach to weight and glucose management
26.87
Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements
26.50
4.2 ★★★★★
Based on 1452 reviews
Sort
Product Reviews
★★★★★ 5
Good quality
Item Package Quantity: 1
Works great, would by it again
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 1, 2026
★★★★★ 2
Don't waste your money.
Item Package Quantity: 1
Did not work!
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on May 7, 2026
★★★★★ 1
Doesn't work
Item Package Quantity: 1
No effect at all on my headlights. Don't waste your money.
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 30, 2026
★★★★★ 5
Well worth the money. And easy to use.
Item Package Quantity: 1
For what it cost, it worked way better than I expected. 👍
WAS THIS REVIEW HELPFUL?YesReportShare
Reviewed in the United States on April 16, 2026
